Nyamavhuvhu21,Mushonga weT cell engager webispecific, epcoritamab, wakapihwa mukana wekutarisa neCenter for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA). Kubvumidzwa uku kwakanangana nevarwere vakuru vane relapse or refractory follicular lymphoma (FL), chikamu chinodiwa zvakanyanya cheB cell malignancies.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Nhamba yeWeChat: 17801183037
Email：myimmnet@163.com
Nezve Epcoritamab
Epcoritamab iantibody yeIgG1-bispecific yakagadzirwa uchishandisa tekinoroji yaGenmab's DuoBody uye inopihwa pasi peganda. Tekinoroji yeGenmab's DuoBody-CD3 yakagadzirirwa kutungamira masero eT ane chepfu nenzira yekusarudza kuti awane mhinduro yekudzivirira muviri kumarudzi emasero anotarisirwa. Epcoritamab yakagadzirirwa kubatana neCD3 pamasero eT uye CD20 pamasero eB panguva imwe chete uye inokonzera kuuraya masero eCD20+ kuburikidza neT-cell.
Nezve Follicular Lymphoma (FL)
FL inowanzova rudzi rwe non-Hodgkin's lymphoma (NHL) rusingaregi (kana kuti runokura zvishoma nezvishoma) runobva kuB-lymphocytes uye ndiyo yechipiri inonyanya kuwanikwa yeNHL inoverengera 20-30 muzana yezvirwere zvese. Vanhu vanosvika 15,000 vanorwara neFL gore rega rega muUSii uye inoonekwa seisingarapiki nekurapa kwakajairika.iii Varwere vanowanzo dzokera shure uye, nekudzokera shure kwega kwega, kuregererwa kwenguva nenguva yekurapwa kunotevera kupfupika.iv Nekufamba kwenguva, shanduko yekupararira kweB-cell lymphoma (DLBCL), rudzi rweNHL rune hutsinye rwakabatana nemigumisiro yakaipa yekurarama, inogona kuitika kune vanopfuura 25 muzana yevarwere veFL.
EPCORE FL-1 (NCT05409066) iongororo yechitatu yekuongorora kuchengetedzeka uye kushanda kwe epcoritamab pamwe ne rituximab ne lenalidomide (R2) zvichienzaniswa ne R2 chete muvarwere vane relapse/refractory (R/R) follicular lymphoma (FL).
Nyamavhuvhu 7,Genmab A/Syakazivisa mhedzisiro yakanaka yemuyedzo wePhase 3 EPCORE FL-1 uchiongorora subcutaneous epcoritamab, antibody ye bispecific, pamwe chete ne rituximab ne lenalidomide (R®2) zvichienzaniswa ne R2 chete yekurapa varwere vakuru vane relapse or refractory (R/R) follicular lymphoma (FL). Chidzidzo ichi chakasangana nematanho ayo maviri ekutanga emhedzisiro yehuwandu hwemhinduro (ORR, p-value <0.0001) uye progression-free survival (PFS, HR 0.21, p-value <0.0001), zvichiratidza mutsauko wakakosha uye une respiratory mumatanho ese ari maviri, zvichideredza njodzi yekufambira mberi kwechirwere kana kufa ne79%.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Nhamba yeWeChat: 17801183037
Email：myimmnet@163.com
Nguva yekutumira: Gunyana-05-2025